卡尔顿因衍生化合物用于向性胆酶抑制的向性胆酶抑制
Filip Pidany1, Jana Kroustkova1, Jaroslav Jenco1
1Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz.
新型阿尔茨海默氏病 (AD) 药物候选物向人类胆固醇化酶 (hBChE) 的药物是从Amaryllidaceae的化物开发出来的. 化合物28和33显示强大的hBChE抑制和有利的类似药物的AD治疗属性.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏病 (AD) 构成一个重大的治疗挑战,但基胆酶 (hBChE) 被确定为缓解症状和修改疾病的关键标.
- 自然存在的化合物,特别是阿马里利氏类化合物,为开发新型hBChE抑制剂提供了有前途的支架.
研究的目的:
- 设计和合成新的hBChE抑制剂,基于卡尔顿因类型的阿马里里里达科藻类基架.
- 评估这些新型化合物作为潜在的AD治疗药物的抑制潜力,药理动力学特性和安全性.
主要方法:
- 合成了一系列具有3和4基基氨酸化学型的化合物.
- 在体外酶分析以确定hBChE抑制活性 (IC50值).
- 用于结合模式阐明,BBB透预测和化学信息学分析 (利宾斯基和维伯规则) 的in silico模拟.
- 在体外评估中枢神经系统可用性,水溶性,代谢稳定性 (微小体和血) 和细胞毒性 (SH-SY5Y和HepG2细胞系).
主要成果:
- 化合物28和33显示出强大的hBChE抑制,其IC50值分别为0.171±0.063μM和0.167±0.018μM.
- 在和体外研究预测了化合物的中枢神经系统可用性和口服生物可用性.
- 化合物33在微体和等离子体矩阵中表现出良好的水溶性和稳定性.
- 化学信息学分析表明符合利宾斯基和维伯的规则,表明适合于口服.
- 细胞毒性测定显示,在相关度下,神经元和肝细胞系中没有显著的毒性.
结论:
- 新的3-和4-基基胺衍生物代表了阿尔茨海默病治疗中hBChE抑制剂的有希望的类别.
- 化合物28和33具有有利的药理学和药理动力学特征,需要进一步研究作为AD的潜在治疗剂.
- 开发的化合物显示出在阿尔茨海默病患者中安全有效的口服管理的强大潜力.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
11:01Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Direct-Acting Cholinergic Agonists: Pharmacokinetics
